Adipotide — 5 mg

Adipotide, also called prohibitin-targeting peptide 1 or prohibitin-TP01, is a designed peptidomimetic with two functional parts. One targets a vascular marker associated with white adipose tissue; the other is intended to damage mitochondria and trigger apoptosis after entering the targeted cells. The conceptual approach is therefore to affect the blood vessels supporting fat tissue rather than directly imitate an appetite hormone or activate a conventional fat-cell metabolic receptor. Umbrella Labs describes the target as prohibitin on blood vessels feeding adipose tissue. [1,2]

Barnhart and colleagues studied the compound in obese Old World monkeys and reported loss of body weight and white adipose tissue together with improved insulin-resistance measures. Their paper links these changes to targeted vascular apoptosis and also discusses reduced food intake during treatment. These are nonhuman-primate observations, not results from an established human weight-loss intervention. The same research program identified dose-related renal findings, including kidney lesions in a formal animal safety study, which form part of the published description. [1] The seller presents adipotide as a laboratory research reagent and cites the monkey study. [2] “Adipotide” therefore identifies a particular targeting construct, not a general name for all fat-reducing peptides.